NasdaqGS:ANNXBiotechs
Does Annexon’s 2026 “Win Year” Milestone Roadmap Reshape The Bull Case For Annexon (ANNX)?
Earlier this month, Annexon, Inc. presented at the 25th Annual Needham Virtual Healthcare Conference, where CEO Douglas E. Love outlined the company’s upcoming clinical and regulatory milestones.
A key takeaway was management’s description of 2026 as a “win year,” highlighting expected GBS regulatory filings, a Phase III geographic atrophy readout, and proof-of-concept data for ANX1502, all supported by a cash runway projected into the second half of 2027.
We’ll now look at how this “win...